Individualized Tau PET Model Outperforms Predictive Power of Braak Staging
By pinpointing where tau pathology starts in a person’s brain, researchers better predicted future spread and determined small changes in tangle load.
NEWS
Paper Alert: Trafficking Variants Cause BACE Buildup in Axons
In mice lacking the recycling protein GGA3, BACE1 trafficking stalls, local Aβ production increases, and axons swell. Does this explain the neuritic dystrophies seen in early AD?
Plasma Aβ Test Wins Approval—Are p-Tau Tests Far Behind?
Regulators in the U.S. and Europe have certified a mass-spectrometry-based blood test for amyloid-β. Plasma phospho-tau markers are poised to come next.
Getting Under Your Skin: Does Vitiligo Elevate Dementia Risk?
In a retrospective study, people with vitiligo had 12 times the risk of developing Alzheimer’s disease than did healthy controls. Why is that?
In Phase 2 Trial, Neflamapimod Aids Cognition in Lewy Body Dementia
After missing primary endpoints in Alzheimer’s trials, this p38 MAPKa inhibitor gained some traction in a test in people with DLB.
Learning Troubles Spied by Smartphone Track with Biomarkers
Remote assessments on a smartphone closely matched tests taken in the clinic. They also may detect slip-ups in learning—an earlier cognitive deficit that arises in preclinical AD.
Aducanumab Still Needs to Prove Itself, Researchers Say
While the FDA weighs aducanumab’s marketing license application, Alzheimer’s researchers agree that the agency’s own statistician correctly assessed the data as weak. Most prefer that one more trial be done.
TRC-PAD Funnel Finally Touches Down
After years of building an online registry, designing selection algorithms, and getting sites up and running, COVID-19 nearly derailed this trial-ready cohort once again. Now, the first participants have reached the final queue.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome F. Hoffmann-La Roche, joining our other exhibitors — Biogen, BioLegend, Abcam, BrainXell, and the Jackson Laboratory.
SPOTLIGHT
Aducanumab Still Needs to Prove Itself, Researchers Say
It’s safe to say we all wanted this to work out. So why did the independent committee advising the FDA unanimously recommend against approving aducanumab now? The biostatisticians, neurologists, and other experts on the panel were troubled by the negative data from the Phase 3 ENGAGE trial, and by discrepancies in the EMERGE and even PRIME trials. The committee wants more data. It turns out Alzheimer’s clinicians do, too. This is a long story, on a topic we care about deeply. Grab your favorite beverage, and settle in for perhaps a difficult read.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 4
- Total Items: 151
-
Jobs
- Total Items: 77
-
Conference Calendar
- New Items: 2
- Total Items: 82
- Member Directory
Latest Comments